- Home
- SNOW vs ALNY Comparison
SNOW vs ALNY Comparison
Compare SNOW & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNOW | ALNY |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.9B | 42.7B |
| IPO Year | 2020 | 2004 |
Fundamental Metrics
Financial Performance| Metric | SNOW | ALNY |
|---|---|---|
| Price | $140.47 | $304.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 43 | 28 |
| Target Price | $248.62 | ★ $471.00 |
| AVG Volume (30 Days) | ★ 7.1M | 961.8K |
| Earning Date | 05-20-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 206.88 |
| EPS | N/A | ★ 2.33 |
| Revenue | ★ $4,683,946,000.00 | $1,037,418,000.00 |
| Revenue This Year | $28.57 | $52.67 |
| Revenue Next Year | $23.41 | $31.48 |
| P/E Ratio | ★ N/A | $134.23 |
| Revenue Growth | ★ 29.16 | 22.88 |
| 52 Week Low | $118.30 | $246.00 |
| 52 Week High | $280.67 | $495.55 |
Technical Indicators
Market Signals| Indicator | SNOW | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 41.55 | 41.46 |
| Support Level | $118.30 | N/A |
| Resistance Level | $157.84 | $337.10 |
| Average True Range (ATR) | 8.90 | 10.14 |
| MACD | 1.67 | -1.72 |
| Stochastic Oscillator | 55.87 | 9.99 |
Price Performance
Historical ComparisonAbout SNOW Snowflake Inc.
Snowflake Inc Founded in 2012, Snowflake is a fully managed platform that consolidates data hosted on different public clouds for centralized analytics and governance. Snowflakes cloud-native architecture allows users to independently scale the compute and storage layers, providing customers with optimized performance at lower costs. The companies data lake and data warehouse products support a variety of use cases, including business analytics, data engineering, and artificial intelligence. Snowflake is widely used by Fortune 2000 companies in financial services, media, and retail sectors.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.